A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Balovaptan (Primary)
- Indications Pervasive child development disorders
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database. (2020-07-06)
- 14 Jul 2021 Status changed from completed to discontinued.
- 20 Jan 2021 Status changed from discontinued to completed.